Post-diagnosis Statin Use and Breast Cancer Recurrence in a Prospective Cohort Study of Early Stage Breast Cancer Survivors

Marilyn L. Kwan, **Laurel A. Habel**, **E. Dawn Flick**, **Charles P. Quesenberry**, and **Bette Caan**
Division of Research, Kaiser Permanente, Oakland, CA, 94612

Abstract

PURPOSE—We examined the association between post-diagnosis statin use (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] inhibitors) and risk of breast cancer recurrence.

MATERIALS AND METHODS—The study included 1945 early-stage breast cancer survivors participating in the Life After Cancer Epidemiology (LACE) Study. Women who were diagnosed from 1997 to 2000 and identified from the Kaiser Permanente Northern California (KPNC) Cancer Registry entered the cohort on average two years post-diagnosis. Information on statin use was obtained from the KPNC pharmacy database. A total of 210 breast cancer recurrences were reported and verified by medical record review. Cox proportional hazard models were used to estimate rate ratios (RR) and 95% confidence intervals (CI).

RESULTS—The mean duration of statin use in the cohort among those who initiated use post-diagnosis was 1.96 years, and lipophilic statins were mainly used (97.8%). Starting statins after diagnosis was suggestive of a decreased risk of breast cancer recurrence (RR = 0.67; 95% CI: 0.39–1.13). Risk of recurrence decreased with increasing duration of statin use after diagnosis (p linear trend = 0.02).

CONCLUSION—Our findings provide initial support for an inverse association between post-diagnosis, lipophilic statin use and risk of breast cancer recurrence.

Keywords

statins; HMG-CoA inhibitors; breast cancer; recurrence; prognosis

INTRODUCTION

Statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] inhibitors) are lipid-lowering drugs that have been proven in clinical trials to prevent cardiovascular disease [1]. They have not only been associated with beneficial effects on heart-related conditions but also with possible anti-carcinogenic activity. For example, laboratory studies have shown that lipophilic statins such as simvastatin and fluvastatin inhibit mammary tumor growth by approximately 50% at doses equivalent to those used in humans for reducing cholesterol [2]. Thus far, observational studies of the association between statins and risk of developing breast cancer have yielded mixed results, with the majority finding no association [3–10]. To our knowledge, no studies have examined statin use and breast cancer prognosis.

Reprint Requests: Marilyn L. Kwan, PhD, Division of Research, Kaiser Permanente, Oakland, CA 94612, 510-891-3521 (phone), 510-891-3106 (fax), Marilyn.L.Kwan@kp.org.

We investigated the potential association between use of statins after breast cancer diagnosis and breast cancer recurrence among participants in the Life After Cancer Epidemiology (LACE) Study, a prospective cohort study of 2292 early-stage breast cancer survivors. Using data from the KPNC pharmacy prescription database, statins were analyzed according to initiation and duration of use after cancer diagnosis.

MATERIALS AND METHODS

Study cohort

The LACE cohort has been described previously [11]. Briefly, the cohort consists of women diagnosed with invasive breast cancer from 1997 to 2000 recruited primarily from the Kaiser Permanente Northern California (KPNC) Cancer Registry (82%) and the Utah Cancer Registry (12%). Additionally, a subset of women who declined participation in the Women's Healthy Eating and Living (WHEL) Trial, a dietary intervention trial to prevent recurrence of breast cancer, was used as a third source of participants (6%). Women were eligible if they were diagnosed from age 18–79 years with a first primary breast cancer (Stage I   1 cm, II, or IIIA), had completed breast cancer treatment (except for adjuvant hormonal therapy), were within 11 to 39 months post-diagnosis (to capture behavioral factors in the early post-diagnosis period and to ensure that women were free of symptoms due to treatment), had no history of other cancer within five years before enrollment, and were recurrence-free at enrollment. Subsequently, after medical record review, any woman who had a breast cancer recurrence, new breast primary, or death within three months after enrollment was deemed ineligible since these events may have been present at enrollment but missed. Therefore, the start of time at risk in the cohort was three months post-enrollment.

Between January 2000 and April 2002, 5656 women who were presumed to meet the LACE eligibility criteria were sent a recruitment package. Of these, 2614 (46%) agreed to participate and completed the questionnaires. Subsequent medical record review to confirm eligibility resulted in 322 exclusions. Reasons for exclusions were breast cancer recurrence, new primary breast cancer, or death within three months after enrollment (37%), incorrect stage (34%), other cancer within the five years before enrollment (10%), prior breast cancer (6%), more than 39 months since diagnosis (6%), incomplete demographic and medical data (3%), still receiving treatment (2%), and language difficulty (2%). The remaining 2292 women constitute the LACE cohort. This analysis was restricted to the 1945 (85%) who were recruited from KPNC because of the availability of automated pharmacy data on this group. The KPNC participants did not differ significantly from other women in the cohort on age, stage of disease, and body mass index (BMI) (not shown). Subjects entered the cohort on average 1.90 years after diagnosis (range: 0.92 to 3.24 years) and were subsequently followed on average for an additional 5.00 years (range: 0.25 to 6.86) post-enrollment. The study was approved by the institutional review boards of Kaiser Permanente Northern California and University of Utah. Written informed consent was obtained from all participating subjects.

Medication use and other covariates

Information on lipid-lowering agents such as label name, generic name, date dispensed, and days supply was obtained from the KPNC pharmacy database for all Kaiser LACE cohort members (n=1945) as of August 24, 2006. To avoid potential confounding by use of lipid-lowering medications before breast cancer diagnosis, individuals who had statin prescriptions (n=134) prior to diagnosis were excluded, thus leaving 1811 subjects for analysis.

Initiation and duration of post-diagnosis use was categorized as 1) unexposed (100 days supply) and exposed (>100 days supply) and 2) unexposed (100 days supply), 101 days – 2 years supply, and >2 years supply, respectively. A record of at least 100 days supply was considered the minimum exposure since Kaiser health insurance plans commonly allow 100 days supply per dispensing for chronic medications. Therefore, greater than 100 days supply was equivalent to at least two or more prescriptions and deemed as regular use. Results were similar when we excluded the small number of concurrent statin and nonstatin antilipemic users from our analysis (*n*=16), so these individuals were retained in the exposure group in our final analyses. Age, race/ethnicity, education, height and weight, smoking status, family history of breast cancer, and breast cancer treatment were collected on the baseline questionnaire at cohort entry. Data on stage, nodal status, and tumor hormone receptor status were obtained from the KPNC Cancer Registry.

Outcomes

Subsequent health outcomes were ascertained semi-annually, and after five years of follow-up annually, by mailed questionnaire and verified by medical record. The average response rate to the mailed health status updates was 84%. All non-respondents were called to complete a report by phone, increasing the response rate to 99%. KPNC computerized mortality files were regularly searched or participant families were contacted for any cohort members not reached (1%). For study subjects who were known to have died, copies of death certificates were obtained and cause of death recorded. Recurrences were defined as subsequent local, regional, or distant disease, and new breast primary cancers in the contralateral breast. Excluding new breast primary cancers from our analysis (*n*=30) did not produce substantially different results, so the outcome was included as a recurrence. For this analysis, 210 breast cancer recurrences (of which 73% were distant metastases) were ascertained through December 12, 2006. Mean follow-up time from cohort entry until the endpoint of recurrence was 2.60 years (range: 0.25 to 6.57).

Data analysis

To compare relevant characteristics of users, Pearson chi-square tests were applied. Follow-up began at date of cohort entry and ended at date of first confirmed cancer recurrence, date of death, study drop-out date, or December 12, 2006, whichever occurred first. Rate ratios (RR) and 95% confidence intervals (CI) for breast cancer outcomes were estimated by delayed entry Cox proportional hazard models, with months since diagnosis as the time scale [12, 13]. Statin use was modeled as a time-dependent covariate for which cumulative use based on days supply of every prescription was updated at each failure time. The delayed entry model ensures that a woman who enrolled in the study *t* years after her initial breast cancer diagnosis was not considered at risk for a possible recurrence prior to *t* years by removing each woman from the risk set between the time of diagnosis and the time of cohort entry. A linear test for trend was estimated by modeling categorical variables of exposure on an ordinal scale. Confidence intervals not overlapping with 1.00 or *p* values < 0.05 were considered consistent with statistical significance.

Age at diagnosis (<45, 45–54, 55–64, 65 years), race (White, Black, Hispanic, Asian, Other), body mass index (<25, 25–29, 30 kg/m^2), cancer stage (Stage I, IIA, IIB, IIIA), and tamoxifen treatment (never, past, current) were included in the final model as confounders because they had a statistically significant effect on the relative risk associated with statin use when added individually to the Cox model. We also looked at whether the associations between statin use and recurrence varied by menopausal status at diagnosis, BMI, tumor hormone receptor status, and stage of initial breast cancer by first generating strata-specific estimates and then including an interaction term in the model to test for statistical

significance. Little evidence was found that the association between exposure and study endpoint varied by the above factors.

RESULTS

Most of the cohort members were white non-smokers who had no family history of breast cancer (Table 1). Women who used statins post-diagnosis were more likely to be older, obese, or postmenopausal at diagnosis compared to non-users. Statin users and non-users were similar with respect to family history of breast cancer, stage of breast cancer, and nodal status (Table 1).

Among the total KP sub-cohort of 1811 subjects used in this analysis, 367 (18.9%) used statins and 36 (1.8%) used nonstatin antilipemic drugs post-diagnosis (Table 2). The mean duration of post-diagnosis use of statins and nonstatin antilipemics was 1.96 and 1.31 years, respectively. Lovastatin was the primary statin prescribed (84.4%), followed by simvastatin (10.9%), atorvastatin (2.5%), and pravastatin (2.2%). Among the nonstatin antilipemics, gemfibrozil was mainly prescribed (61.1%), followed by niacin (22.2%), cholestyramine (8.3%), colestipol (5.6%), and ezetimibe (2.8%).

Use of statins for more than 100 days after diagnosis compared to use less than or equal to 100 days was associated with a non-statistically significant reduction in risk of breast cancer recurrence (RR = 0.67; 95% CI: 0.39–1.13), adjusting for age at diagnosis, race, body mass index, stage of breast cancer, and tamoxifen treatment (Table 3). Risk of breast cancer recurrence decreased with increasing duration of post-diagnosis statin use (*p* for linear trend = 0.02) (Table 3). The association between post-diagnosis use of nonstatin antilipemics and recurrence could not be examined adequately since the number of users was small (*n*=36), thereby producing unstable risk estimates (not shown).

DISCUSSION

To our knowledge, our study is the first to examine the potential relationship between use of statins and breast cancer prognosis. We found that use of primarily lipophilic statins after diagnosis appeared to be associated with a reduced risk of recurrence, and that this risk decreased with increasing duration of use. Given the largely non-statistically significant results, the impact of chance cannot be ruled out.

Biological evidence exists which supports a possible protective role of statins, particularly lipophilic statins, on breast cancer outcomes [14]. It appears that only lipophilic statins influence cell proliferation, survival, and motility by permeating the cell membrane [15], specifically extrahepatic cell membranes [16]. *In vitro* laboratory studies have found that lipophilic statins can inhibit the proliferation of breast cancer cells [2, 17–19], with critical proteins regulating cell survival and proliferation mechanisms being most influenced by statin treatment [2]. Interestingly, this reduction in cell proliferation was stronger in estrogen receptor (ER) -negative cells, suggesting that ER-negative cell lines might be more sensitive to growth inhibition by statins than ER-positive cell lines [2, 17, 20]. However, in our study, we did not observe a difference in the association of statin use and breast cancer recurrence by hormone receptor status, which could be due to small subgroup sizes and thus limited statistical power. In addition, *in vivo* mouse mammary tumor models demonstrated that lovastatin, fluvastatin, and simvastatin decreased tumor formation and/or inhibited metastasis [2, 21, 22]. Furthermore, three clinical studies, including one randomized trial, suggest that statins may enhance standard chemotherapy or radiotherapy for treatment of cancers such as prostate, rectal, and hepatoma at doses used for cardiovascular disease [15].

Observational studies thus far have yielded mixed results regarding the effect of statins on breast cancer incidence. A large case-control study from the General Practice Research Database, an automated database containing drug prescription and medical information on more than three million people in the United Kingdom, found no association between current statin use and breast cancer risk [10]. Interestingly, another large case-control study with cases from a population-based tumor registry reported no overall association of statins with breast cancer incidence but did find that women who had used statins for more than five years had an approximately 30% lower breast cancer incidence than never users [4]. Two other case-control studies observed no association between statin use and breast cancer risk [6, 9]. Similarly, four large cohort studies found no association between statin use and risk of breast cancer [3, 5, 7, 8], although one study observed an 18% lower breast cancer incidence with use of lipophilic statins [5]. A meta-analysis [23] conducted in late 2005 of nine observational studies, including those mentioned above, and seven clinical trials found that statin use did not significantly affect the risk of breast cancer using either a fixed-effects model (RR = 1.03; 95% CI: 0.93–1.14) or random effects model (RR = 1.02; 95% CI = 0.89–1.18). Stratification by study design did not appreciably change the effect estimates. Notably, this meta-analysis did not include two large retrospective studies, both of which suggested a protective benefit of statin use on breast cancer risk [24, 25].

Strengths of this study include being one of the few existing cohorts of early-stage breast cancer survivors, one of the first studies to examine the association of post-diagnosis statin use and breast cancer outcomes, and use of pharmacy prescription data such that recall bias is not a methodological issue. In addition, almost all Kaiser members have pharmacy benefits and thus fill their prescriptions at a Kaiser pharmacy, thereby assuring nearly complete capture of medication dispensings [26]. A limitation of this study is the inability to examine the impact of lipophilic compared to lipophobic statins on breast cancer endpoints since only eight participants had a record of lipophobic statin use, yet our data were homogeneous in terms of statin lipophilicity. In addition, we could not adequately examine confounding by indication with comparison to nonstatin antilipemics due to limited numbers, and the pharmacy database does not contain information on indication. Thus, one cannot exclude the possibility that statin use could be a surrogate for the effect of an associated condition like hyperlipidemia. When interpreting our results, one should also consider that long-term statin users (five years or more) tend to be healthier and more adherent to therapy and screening than non-users such that our risk estimates could be biased towards a protective effect [27]. Considering that the average duration of post-diagnosis statin use in our cohort was more short-term (1.96 years), the impact of this bias would most likely be minimal. Finally, our results cannot be generalized to recurrences that may have occurred in the early post-diagnosis period because women did not enter the cohort until they had completed chemotherapy and/or radiation treatment (on average two years post-diagnosis),

In conclusion, our study provides initial support for an inverse association between primarily lipophilic statins and risk of breast cancer recurrence. Given our results and the fact that statins are currently among the most widely prescribed drugs in the U.S. [28], more studies are warranted to fully assess the anti-oncogenic potential of statins on breast cancer prognosis.

Acknowledgments

References

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267–78. [PubMed: 16214597]

2. Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006; 66(17):8707–14. [PubMed: 16951186]

3. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol. 2003; 56(3):280–5. [PubMed: 12725884]

4. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004; 100(11):2308–16. [PubMed: 15160333]

5. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006; 98(10):700–7. [PubMed: 16705124]

6. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002; 13(3):262–7. [PubMed: 11964926]

7. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005; 165(19):2264–71. [PubMed: 16246993]

8. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005; 114(4):643–7. [PubMed: 15578694]

9. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004; 22(12):2388–94. [PubMed: 15197200]

10. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90(3):635–7. [PubMed: 14760377]

11. Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML. Life After Cancer Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States). Cancer Causes Control. 2005; 16(5):545–56. [PubMed: 15986109]

12. Allison, PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Press; 1995.

13. Hosmer, DW.; Lemeshow, S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons, Inc; 1999.

14. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005; 5(12):930–42. [PubMed: 16341084]

15. Katz MS. Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005; 2(2):82–9. [PubMed: 16264880]

16. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev. 2005; 14(8):1897–8. [PubMed: 16103434]

17. Esserman L, Campbell M, Shoemaker M, Lobo M, Marx C, Benz C. Breast cancer inhibition by statins. J Clin Oncol. 2004; 22(97s suppl):abstr 1003.

18. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause. 2003; 10(4): 332–6. [PubMed: 12851516]

19. Seeger H, Wallwiener D, Mueck AO. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes. 2003; 111(1):47–8. [PubMed: 12605351]

20. Kumar AS, Campbell M, Benz CC, Esserman LJ. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006; 24(13):2127. author reply 2127–8. [PubMed: 16648516]

21. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat. 1998; 50(1):83–93. [PubMed: 9802623]

22. Farina HG, Bublik DR, Alonso DF, Gomez DE. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis. 2002; 196:551–9. [PubMed: 12405293]

23. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005; 23(34): 8606–12. [PubMed: 16260694]

24. Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C. Statins to reduce breast cancer risk: A case control study in U.S. female veterans. J Clin Oncol. 2005; 23(7s suppl):abstr 514.

25. Mortimer J, Axelrod R, Zimbro K. Effect of statins on breast cancer incidence: Findings from the Sentara Health Plan. Proc Am Soc Clin Oncol. 2004; 22(93):abstr 373.

26. Selby, JV.; Smith, DH.; Johnson, ES.; Raebel, MA.; Friedman, GD.; McFarland, BH. Kaiser Permanente Medical Care Program. In: SBL, editor. Pharmaco epidemiology. John Wiley & Sons, Ltd; West Sussex: 2005. p. 241-259.

27. Setoguchi S, Avorn J, Schneeweiss S. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 353(9):952–4. author reply 952–4. [PubMed: 16136709]

28. [Last accessed: December 12, 2006] The Internet Drug Index. http://www.rxlist.com

Table 1

Demographic characteristics and breast cancer risk factors by post-diagnosis statin use obtained from the KPNC pharmacy database in the LACE Study, 2000–2006

	Yes Statin Use *n* (%)	No Statin Use[a] *n* (%)	*p* value[b]
Age at diagnosis (years)			<0.001
<45	12 (3.3)	195 (13.5)	
45 – 54	78 (21.2)	469 (32.5)	
55 – 64	124 (33.8)	398 (27.6)	
65	153 (41.7)	382 (26.4)	
Mean ± Standard Deviation	62.2 ± 9.4	57.2 ± 11.1	
Race/ethnicity			0.02
White	284 (77.6)	1132 (78.5)	
Black	32 (8.8)	67 (4.7)	
Hispanic	18 (4.9)	103 (7.1)	
Asian	22 (6.0)	98 (6.8)	
Other	10 (2.7)	42 (2.9)	
Unknown	1	2	
Education			0.05
HS diploma/GED	113 (30.9)	362 (25.1)	
Some college	137 (37.4)	547 (38.0)	
College degree	116 (31.7)	532 (36.9)	
Unknown	1	3	
Body mass index (BMI) at prediagnosis (kg/m^2)			<0.001
<25	123 (33.5)	734 (50.8)	
25 – 29	123 (33.5)	414 (28.7)	
30	121 (33.0)	296 (20.5)	
Mean ± Standard Deviation	28.5 ± 5.8	26.3 ± 5.7	
Menopausal status at diagnosis[c]			<0.001
Premenopausal	41 (12.9)	383 (30.7)	
Postmenopausal	276 (87.1)	863 (69.3)	
Unknown	50	198	
Family history of breast cancer			0.73
No	295 (80.4)	1148 (79.6)	
Yes	72 (19.6)	295 (20.4)	
Unknown	0	1	
Radiation therapy			0.04
No	147 (40.7)	494 (35.0)	
Yes	214 (59.3)	916 (65.0)	
Unknown	6	34	
Chemotherapy			<0.01
No	189 (51.8)	609 (42.5)	
Yes	176 (48.2)	824 (57.5)	

	Yes Statin Use *n* (%)	No Statin Use[a] *n* (%)	*p* value[b]
Unknown	2	11	
Tamoxifen			<0.01
Never	104 (28.7)	301 (21.2)	
Past	26 (7.2)	90 (6.3)	
Current	232 (64.1)	1028 (72.5)	
Unknown	5	25	
Aromatase Inhibitor			0.04
No	221 (72.2)	761 (66.1)	
Yes	85 (27.8)	391 (33.9)	
Unknown	61	292	
Stage of breast cancer			0.52
Stage I	182 (49.6)	665 (46.1)	
Stage IIA	122 (33.2)	484 (33.6)	
Stage IIB	54 (14.7)	248 (17.2)	
Stage IIIA	9 (2.5)	45 (3.1)	
Unknown	0	2	
Nodal status			0.15
Negative	242 (66.3)	871 (62.3)	
Positive	123 (33.7)	528 (37.7)	
Unknown	2	45	
Estrogen/Progesterone receptor status			0.07
Neg/Neg	68 (18.5)	207 (14.5)	
Neg/Pos	9 (2.5)	18 (1.3)	
Pos/Neg	48 (13.1)	210 (14.7)	
Pos/Pos	242 (65.9)	994 (69.6)	
Unknown	0	15	
Total	367	1444	1811

[a] No statin use includes 100 days supply obtained from KPNC pharmacy database.

[b] From Pearson chi-square test.

[c] Premenopausal at diagnosis includes less than 60 years old at diagnosis, had period within three months prior to diagnosis, and not on estrogen hormone therapy (HT) prior to diagnosis; Postmenopausal at diagnosis includes the following four scenarios: 1) greater than or equal to 60 years old at diagnosis or periods stopped 12 months or more before diagnosis (excludes women who had a hysterectomy only before diagnosis, with last period within seven months of hysterectomy), 2) less than 60 years old at diagnosis and had oophorectomy and hysterectomy any time before diagnosis, with periods stopping at the same time as surgery, 3) less than 60 years old at diagnosis and had oophorectomy without hysterectomy before diagnosis, with HT beginning around oophorectomy date, 4) less than 60 years old at diagnosis and had oophorectomy without hysterectomy before diagnosis date, with periods stopping at same time as oophorectomy and having no HT before diagnosis; Unknown includes any scenario not covered above.

Table 2

Post-diagnosis use of statins and nonstatin antilipemics obtained from the KPNC pharmacy database in the LACE Study, 2000–2006

	n	*%*
Total Cohort	1811	100.0
Statin Use (Post-diagnosis)[a]	367	20.3
Nonstatin Antilipemic Use (Post-diagnosis)[a]	36	2.0
None (Post-diagnosis)	1408	77.7
Statin Use (Post-diagnosis)	367	100.0
Lovastatin[b]	310	84.4
Simvastatin[b]	40	10.9
Atorvastatin[b]	9	2.5
Pravastatin	8	2.2
Nonstatin Antilipemic Use (Post-diagnosis)	36	100.00
Gemfibrozil	22	61.1
Niacin	8	22.2
Cholestyramine	3	8.3
Colestipol	2	5.6
Ezetimibe	1	2.8

[a]Includes 16 concurrent post-diagnosis statin and nonstatin antilipemic users

[b]Lipophilic statins

Table 3

Relative risks of breast cancer recurrence and post-diagnosis statin use obtained from the KPNC pharmacy database in the LACE Study, 2000–2006

	Recurrences[a] *n* (%)	No Recurrences *n* (%)	Unadjusted RR (95% CI)	Adjusted[b,c] RR (95% CI)
Any Statin				
No (100 days supply)	194 (92.4)	1273 (79.5)	1.00 (reference)	1.00 (reference)
Yes (>100 days supply)	16 (7.6)	328 (20.5)	0.76 (0.46–1.28)	0.67 (0.39–1.13)
No Use (100 days supply)	194 (92.4)	1273 (79.5)	1.00 (reference)	1.00 (reference)
101 days – 2 years supply	13 (6.2)	187 (11.7)	0.95 (0.54–1.67)	0.80 (0.45–1.43)
>2 years supply	3 (1.4)	141 (8.8)	0.41 (0.13–1.29)	0.38 (0.12–1.19)
Total duration of use (years)	Median: 1.37		Mean: 1.96	

[a] 210 total breast cancer recurrences (27 local and regional recurrences, 153 distant recurrences, and 30 new breast cancers in the contralateral breast) where mean and median follow-up time to recurrence was 2.60 years and 2.39 years, respectively.

[b] Derived from Cox proportional hazard models with left truncation treating statins as a time-dependent covariate and outcomes censored on December 12, 2006.

[c] Adjusted for age at diagnosis, race, body mass index, stage of breast cancer, and tamoxifen treatment, as delineated in Table 1.